New hope for tough breast cancer: phase 3 trial launches
Disease control
Not yet recruiting
This study compares a new drug, 9MW2821, to standard chemotherapy in people with advanced triple-negative breast cancer that has already been treated with certain chemotherapies and antibody-drug conjugates. The main goal is to see if 9MW2821 helps people live longer. About 356 p…
Phase: PHASE3 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC